Hamlet BioPharma AB publ (XSAT:HAMLET B) EV-to-EBITDA : -18.78 (As of Jun. 28, 2025)

Hamlet BioPharma AB publ EV-to-EBITDA Chart

Hamlet BioPharma AB publ Annual Data
	Trend	Jun15	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23	Jun24
EV-to-EBITDA		Get a 7-Day Free Trial					-28.98	-110.05	-22.88	-14.74	-20.39

Hamlet BioPharma AB publ Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBITDA	Get a 7-Day Free Trial															-9.61	-20.39	-20.16	-16.40	-17.72

Competitive Comparison of Hamlet BioPharma AB publ's EV-to-EBITDA

For the Biotechnology subindustry, Hamlet BioPharma AB publ's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hamlet BioPharma AB publ's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hamlet BioPharma AB publ's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Hamlet BioPharma AB publ's EV-to-EBITDA falls into.

Hamlet BioPharma AB publ EV-to-EBITDA Calculation

Hamlet BioPharma AB publ's EV-to-EBITDA for today is calculated as:

Hamlet BioPharma AB publ's current Enterprise Value is kr726.25 Mil.
Hamlet BioPharma AB publ's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-38.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hamlet BioPharma AB publ  (XSAT:HAMLET B) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Hamlet BioPharma AB publ's PE Ratio (TTM) for today is calculated as:

Hamlet BioPharma AB publ's share price for today is kr4.20.
Hamlet BioPharma AB publ's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.281.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Hamlet BioPharma AB publ EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Hamlet BioPharma AB publ's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Hamlet BioPharma AB publ Business Description